Search results
Results from the WOW.Com Content Network
Acetylcysteine is the N-acetyl derivative of the amino acid L-cysteine, and is a precursor in the formation of the antioxidant glutathione in the body. The thiol (sulfhydryl) group confers antioxidant effects and is able to reduce free radicals .
The natural somatostatin receptor ligand, the 14 amino acid peptide somatostatin (A), was abridged to the biologically more stable 8 amino acid peptide Octreotide (OC, B). Introduction of a tyrosine into the 3rd position of the Octreotide sequence resulted in Tyr3-Octreotide (TOC, C), which allows for iodination of the tyrosine residue with the ...
Teduglutide differs from natural GLP-2 by a single amino acid: an alanine is replaced with a glycine. This blocks breaking down of the molecule by dipeptidyl peptidase and increases its half-life from seven minutes (GLP-2) to about two hours, while retaining its biological actions.
Desmopressin (1-deamino-8-D-arginine vasopressin) is a synthetic form of the normal human hormone arginine vasopressin (the antidiuretic hormone, or ADH), a peptide containing nine amino acids. Compared to vasopressin, desmopressin's first amino acid has been deaminated , and the arginine at the eighth position is in the dextro rather than the ...
To protect them, an amino acid solution (arginine/lysine) is administered by slow infusion, starting before the radioactive administration and normally continuing for several hours afterwards. [ 9 ] [ 12 ] [ 13 ]
Side effects are rare; [2] they include changes in color vision, seizures, blood clots, and allergic reactions. [2] Tranexamic acid appears to be safe for use during pregnancy and breastfeeding. [2] [10] Tranexamic acid is an antifibrinolytic medication. [11] Tranexamic acid was first made in 1962 by Japanese researchers Shosuke and Utako ...
Common side effects include infections, acute infusion reactions, and abdominal pain. [23] Infliximab is a chimeric monoclonal antibody biologic . It seems to work by binding to and neutralizing TNF-α , preventing it from interacting with its receptors on the cell. [ 23 ]
[2] [5] It is a fixed-dose combination of foscarbidopa, an aromatic amino acid decarboxylation inhibitor and prodrug for carbidopa; [5] and foslevodopa, an aromatic amino acid and prodrug for levodopa that was developed by AbbVie.